SCHEMBL5025326

SCHEMBL5025326

COc1ccc2oc3ccc(I)cc3c2c1C(=O)Nc1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
GAA P10253 1/20 0.51
RAB9A P51151 7/20 0.50
NPC1 O15118 6/20 0.50
TP53 P04637 3/20 0.50
MAPT P10636 5/20 0.48
KDM4E B2RXH2 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
TSHR P16473 1/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 2/20 0.47
HSD17B10 Q99714 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5018011 0.89 ALDH1A1 (0.53) LMNARAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL5018084 0.88 NPC1 (0.62) LMNAGAARAB9ANPC1TP53
SCHEMBL5022893 0.85 GAA (0.53) LMNAGAARAB9ANPC1TP53
SCHEMBL5026608 0.85 KMT2A (0.57) LMNAGAARAB9ANPC1TP53
SCHEMBL5016436 0.78 SMN1; SMN2 (0.50) LMNARAB9ANPC1TP53MAPT
SCHEMBL5016527 0.77 ALDH1A1 (0.53) LMNARAB9ANPC1MAPTKDM4E
SCHEMBL5022678 0.75 KDM4E (0.49) LMNARAB9ANPC1TP53MAPT
SCHEMBL5017917 0.74 POLB (0.54) LMNAMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL5023320 0.74 NPC1 (0.59) LMNAGAARAB9ANPC1MAPT
SCHEMBL4034779 0.74 GAA (0.53) LMNAGAARAB9ANPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2008-06-19 US disclosed
EP-1554262-B1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS LTD (IN) 2007-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LTC4S, TSLP, GPR119 LMNA 2873/4885GAA 681/4885RAB9A 3448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.